CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation

Area of Science:

• Hematology
• Stem Cell Biology
• Gene Editing

Background:

• The chemokine CXCL4/platelet factor 4 (PF4) is implicated in myelofibrosis pathogenesis.
• Polycythemia vera (PV) is a myeloproliferative neoplasm often associated with the JAK2 V617F mutation.
• Understanding CXCL4's role in PV and myelofibrosis requires specific cellular models.

Purpose of the Study:

• To generate CXCL4 knockout (CXCL4^KO) induced pluripotent stem cells (iPS cells) from a PV patient.
• To create iPS cell lines with and without the JAK2 V617F mutation for comparative studies.
• To establish a tool for investigating the function of CXCL4 in hematological diseases.

Main Methods:

• CRISPR/Cas9 gene editing was employed to knock out the CXCL4 gene in patient-derived iPS cells.
• Two distinct CXCL4^KO iPS cell lines were generated: one carrying the JAK2 V617F mutation and one without.
• Pluripotency was confirmed through standard assays, including marker expression and trilineage differentiation potential.

Main Results:

• Successful deletion of exon 1 of the CXCL4 gene was confirmed in the generated iPS cell lines.
• Complete loss of CXCL4 protein expression was observed in the CXCL4^KO iPS cells.
• The generated iPS cells maintained pluripotency, demonstrating their suitability for further research.

Conclusions:

• The study successfully generated functional CXCL4^KO iPS cell lines from a polycythemia vera patient.
• These cell lines represent a valuable preclinical tool for dissecting the specific contributions of CXCL4 in myelofibrosis and PV.
• Further research using these models is expected to elucidate the role of CXCL4 in human disease pathogenesis.